Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640341 · ClinicalTrials.gov registry record · Phase 4
Comparative Performance of PureVision, Acuvue Oasys and O2Optix
A Phase 4 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 4
- Development phase
- 510
- Enrollment target
NCT00640341: Completed Phase 4 study, sponsored by Bausch & Lomb Incorporated.
NCT00640341 is a Phase 4 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 510 participants, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00640341, a Phase 4 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 510 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the performance of the PureVision Contact Lens compared to Acuvue Oasys Contact lens and O2Optix Contact lens when worn on a daily wear basis.
Primary Outcome
All dispensed eyes over all follow-up visits. Measured on a scale of 0-4 with 0=no findings and 4=severe findings. Epithelial edema, epithelial microcysts, corneal staining, limbal \& bulbar injection, conjunctival abnormalities, corneal neovascularization and infiltrates were measured.
Interventions
- DEVICE PureVision Contact Lens
- DEVICE Acuvue Oasys Contact Lens
- DEVICE O2Optix Contact lens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
What the finished NCT00640341 record still lists
NCT00640341 is an interventional study that assigns participants to a tested intervention. The registered 510 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which PureVision Contact Lens is the first listed.
NCT00640341 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00640341 about?
NCT00640341 is a clinical study titled "Comparative Performance of PureVision, Acuvue Oasys and O2Optix". The objective of this study is to evaluate the performance of the PureVision Contact Lens compared to Acuvue Oasys Contact lens and O2Optix Contact lens when worn on a daily wear basis.
What is the current status of trial NCT00640341?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 510 participants. The study started on 2008-02. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00640341?
The interventions under investigation include: PureVision Contact Lens (DEVICE), Acuvue Oasys Contact Lens (DEVICE), O2Optix Contact lens (DEVICE).
Who is sponsoring clinical trial NCT00640341?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00640341's enrollment target sits among peer trials
510 162nd of 2000 higher than 1,839 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia